NasdaqGM:TNGXBiotechs
A Look At Tango Therapeutics (TNGX) Valuation After Q4 Results And Pipeline Update
Insider sale follows Q4 results and pipeline update
Tango Therapeutics (TNGX) drew fresh attention after strong fourth quarter results and drug pipeline updates, as its President of R&D, Adam Crystal, disclosed a scheduled sale of 20,251 shares on March 5, 2026.
See our latest analysis for Tango Therapeutics.
After the Q4 release and pipeline update, Tango Therapeutics' recent 1 day share price return of 8.9% and 30 day share price return of 81.44% come on top of a very large 1 year total...